Core Insights - A recent survey by Guardant Health and Harris Poll reveals that 92% of Americans aged 45 and over believe that blood-based colorectal cancer screening should be accessible and covered without co-pay, similar to Medicare [1] - The Shield test by Guardant Health, a non-invasive blood-based screening for colorectal cancer, has shown a 93% adherence rate, significantly improving screening rates compared to traditional methods [1] - The survey highlights barriers to colorectal cancer screening, with 54% of respondents finding stool-based tests unappealing and 71% expressing anxiety about colonoscopies [1] Company Overview - Guardant Health is a leading precision oncology company focused on enhancing patient care and accelerating cancer therapies through advanced blood and tissue tests [1] - The Shield test is the first and only FDA-approved blood test for primary colorectal cancer screening, intended for individuals aged 45 and older at average risk [1] - Guardant Health's Shield test is covered by Medicare, Veterans Affairs Community Care Network, and TRICARE, making it widely accessible across the U.S. [1] Industry Context - Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with a 91% five-year survival rate if detected early [1] - The U.S. Preventive Services Task Force updated national CRC screening guidelines in 2021, lowering the recommended screening age from 50 to 45, but has yet to include the new Shield test in its recommendations [1] - The National Comprehensive Cancer Network has recently included the Shield blood test in its updated CRC screening guidelines, indicating a shift towards improved patient access [1]